These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19159911)

  • 1. [B lymphocytes: a new "target" in treatment for multiple sclerosis].
    Hohlfeld R
    Nervenarzt; 2009 Feb; 80(2):147-8. PubMed ID: 19159911
    [No Abstract]   [Full Text] [Related]  

  • 2. [Targeting B cells in multiple sclerosis. Current concepts and strategies].
    Menge T; Büdingen HC; Dalakas MC; Kieseier BC; Hartung HP
    Nervenarzt; 2009 Feb; 80(2):190-8. PubMed ID: 19189075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bedside to bench: betting on B cells in multiple sclerosis.
    Link H
    Nat Med; 2008 Jun; 14(6):615-6. PubMed ID: 18535578
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab and multiple sclerosis.
    Kitsos DK; Tsiodras S; Stamboulis E; Voumvourakis KI
    Clin Neuropharmacol; 2012; 35(2):90-6. PubMed ID: 22421587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocrelizumab: A New Therapeutic Paradigm for Multiple Sclerosis
    Chin P; Chan AC
    Biochemistry; 2018 Feb; 57(5):474-476. PubMed ID: 29172456
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of B cells in multiple sclerosis: implications for B-cell-targeted therapy.
    Hirotani M; Niino M; Sasaki H
    Curr Med Chem; 2010; 17(28):3215-22. PubMed ID: 20666723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune diseases. The B cell slayer.
    Matthews R
    Science; 2007 Nov; 318(5854):1232-3. PubMed ID: 18033858
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to "'Thinking without thinking' about natalizumab and PML".
    Houff S; Berger JR
    J Neurol Sci; 2008 Jan; 264(1-2):198-9; author reply 199. PubMed ID: 17936798
    [No Abstract]   [Full Text] [Related]  

  • 9. B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies.
    Cencioni MT; Mattoscio M; Magliozzi R; Bar-Or A; Muraro PA
    Nat Rev Neurol; 2021 Jul; 17(7):399-414. PubMed ID: 34075251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-Cell Depletion - A Frontier in Monoclonal Antibodies for Multiple Sclerosis.
    Calabresi PA
    N Engl J Med; 2017 Jan; 376(3):280-282. PubMed ID: 28001486
    [No Abstract]   [Full Text] [Related]  

  • 11. B cells in multiple sclerosis therapy-A comprehensive review.
    Rahmanzadeh R; Weber MS; Brück W; Navardi S; Sahraian MA
    Acta Neurol Scand; 2018 Jun; 137(6):544-556. PubMed ID: 29512131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.
    Nguyen AL; Gresle M; Marshall T; Butzkueven H; Field J
    Br J Pharmacol; 2017 Jul; 174(13):1895-1907. PubMed ID: 28319650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating multiple sclerosis with monoclonal antibodies.
    Buttmann M; Rieckmann P
    Expert Rev Neurother; 2008 Mar; 8(3):433-55. PubMed ID: 18345973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.
    Kinzel S; Weber MS
    CNS Drugs; 2016 Dec; 30(12):1137-1148. PubMed ID: 27844213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of B cells and autoantibodies in multiple sclerosis.
    Archelos JJ; Storch MK; Hartung HP
    Ann Neurol; 2000 Jun; 47(6):694-706. PubMed ID: 10852535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD21 positive B cell: a novel target for treatment of multiple sclerosis.
    Farjam M; Ebrahimpour A; Fakhraei B
    Med Hypotheses; 2013 May; 80(5):556-7. PubMed ID: 23384704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoregulatory T cells in multiple sclerosis: markers and functions.
    Bach MA
    Springer Semin Immunopathol; 1985; 8(1-2):45-56. PubMed ID: 2860727
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatments.
    Galimberti D; Bresolin N; Scarpini E
    Expert Rev Neurother; 2004 May; 4(3):439-53. PubMed ID: 15853541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B cell-directed therapies in multiple sclerosis.
    Gasperi C; Stüve O; Hemmer B
    Neurodegener Dis Manag; 2016; 6(1):37-47. PubMed ID: 26782316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoregulation in multiple sclerosis.
    Arnason BG; Antel JP; Reder AT
    Ann N Y Acad Sci; 1984; 436():133-9. PubMed ID: 6241817
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.